The Myeloma Beacon » Tanespimycin (KOS-953, 17-AAG)

Tanespimycin (KOS-953, 17-AAG)

By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled

Brand Name:
Generic Name:	tanespimycin
Code Names:	KOS-953, 17-AAG
Company:	Bristol-Myers Squibb / Kosan Biosciences
FDA Clinical Phase:	clinical development halted

Description:
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.

Clinical Trials:
For a list of clinical trials studying tanespimycin for the treatment of multiple myeloma, see ClinicalTrials.gov ^[1].

Beacon news: BMS Halts Development Of Tanespimycin ^[2]

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2008/10/15/tanespimycin/

URLs in this post:

[1] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=&recr=&rslt=&type=&cond=multiple+myeloma&intr=tanespimycin&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

[2] BMS Halts Development Of Tanespimycin: https://myelomabeacon.org/news/2010/07/22/tanespimycin-development-halted/

Click here to print.